Subscribe to RSS
Download PDF
DOI: 10.1055/a-2705-9462
Developing New Pyrido[2,3-d]pyrimidine-Based Small Molecules as Potent ATR Inhibitors
Authors
Abstract
Ataxia Telangiectasia and Rad3-related (ATR), a key enzyme of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, that plays a vital role in controlling the DNA damage response (DDR). ATR has become more essential for the survival of tumour cells that have deficiencies in the ataxia telangiectasia mutated (ATM) gene or a lack of DDR function. This indicates that ATR is an important target for anticancer drugs due to its synthetic lethality. In this article, we present a potent and highly selective pyrido[2,3-d]pyrimidine based novel ATR inhibitor. All the synthesized compounds were characterized by using 1H NMR, 13C NMR, and HRMS analysis, and they were all produced in good to excellent yields. In silico studies were conducted on a synthesized compound (4a) using density functional theory (DFT) at B3LYP/6-311++G(d,p) level. Results showed good predictions for pharmacokinetics, medicinal properties, physicochemical, and lipophilicity. ADMET studies predicted target molecule properties and simulated molecular docking between ligand and receptors.
Publication History
Received: 29 July 2025
Accepted after revision: 29 August 2025
Accepted Manuscript online:
19 September 2025
Article published online:
10 November 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Pilie PG, Tang C, Mills GB, Yap TA. Nat Rev Clin Oncol 2019; 16: 81-104
- 2 Baxter JS, Zatreanu D, Pettitt SJ, Lord CJ. Mol Oncol 2022; 16: 3811-3827
- 3 Maleki Dana P, Sadoughi F, Mirzaei H, Asemi Z, Yousefi B. Eur J Pharmacol 2022; 924: 174957
- 4 Sugimoto K. Curr Genet 2018; 64: 965-970
- 5 Schlam-Babayov S, Ziv Y, Shiloh Y. Mol Cell Oncol 2021; 8: 1881395
- 6 Dobbs TA, Tainer JA, Lees-Miller SP. DNA Repair 2010; 9: 1307-1314
- 7 Qiu Z, Oleinick NL, Zhang J. Radiother Oncol 2018; 126: 450-464
- 8 Pennisi R, Antoccia A, Leone S, Ascenzi P, di Masi A. FEBS J 2017; 284: 2378-2395
- 9 Kamp JA, Lemmens B, Romeijn RJ. et al. Nucleic Acids Res 2022; 50: 6235-6250
- 10 Cheng A, Tse KH, Chow HM. et al. Autophagy 2021; 17: 1998-2010
- 11 Neeb A, Herranz N, Arce-Gallego S. et al. Eur Urol 2021; 79: 200-211
- 12 Marechal A, Zou L. Cold Spring Harb Perspect Biol 2013; 5: a012716
- 13 Matsuoka S, Ballif BA, Smogorzewska A. et al. Science 2007; 316: 1160-1166
- 14 Faulhaber EM, Jost T, Symank J. et al. Genes 2021; 12: 925
- 15 Bi X, Srikanta D, Fanti L. et al. Proc Natl Acad Sci U S A 2005; 102: 15167-15172
- 16 Knegtel R, Charrier JD, Durrant S. et al. J Med Chem 2019; 62: 5547-5561
- 17 Foote KM, Nissink JWM, McGuire T. et al. J Med Chem 2018; 61: 9889-9907
- 18 Jo U, Senatorov IS, Zimmermann A. et al. Mol Cancer Ther 2021; 20: 1431-1441
- 19 Roulston A, Zimmermann M, Papp R. et al. Mol Cancer Ther 2022; 21: 245-256
- 20 Lucking U, Wortmann L, Wengner AM. et al. J Med Chem 2020; 63: 7293-7325
- 21 Sanmartín C, Domínguez MV, Cordeu L. et al. Arch Pharm Pharm Med Chem 2008; 341: 28-41
- 22 Font M, González A, Palop JA, Sanmartín C. J Mol Struct.
- 23 Malagu K, Duggan H, Menear K. et al. Med Chem Lett 2009; 19: 5950-5953
- 24 Khalymbadzha IA, Fatykhov RF, Chupakhin ON. et al. Synthesis 2018; 50 (12) 2423-2431
- 25 Kim NY, Cheon C-H. Tetrahedron Lett 2014; 55: 2340
- 26 Frisch MJ, Trucks GW, Schlegel HB. et al. Gaussian 16, Revision C.01. Wallingford CT: Gaussian, Inc.; 2016
- 27 Dennington R, Keith TA, Millam JM. GaussView, Version 6.1. Mission KS: Gaussian, Inc.; 2016
- 28 Ghous F, Shukla S, Rai S, Afza N, Singh R, Bishnoi A. Chem Data Collect 2022; 41: 100933
- 29 Ghous F, Shukla S, Singh R, Parveen S, Banerjee M, Bishnoi A. J Mol Struct 2023; 1285: 135462
- 30 Afza N, Fatma S, Ghous F. et al. J Mol Struct 2023; 1276: 134721
- 31 Ghous F, Shukla S, Parveen S, Kumar S, Banerjee M, Bishnoi A. J Mol Struct 2024; 1304: 137578
- 32 Rai S, Ghous F, Shukla S, Sharma P, Trivedi P, Bishnoi A. J Mol Struct 2023; 1292: 136116
- 33 Issa NT, Wathieu H, Ojo A, Byers SW, Dakshanamurthy S. Curr Drug Metab 2017; 18: 556-565
- 34 Lombardo F, Desai V, Arimoto R. et al. J Med Chem 2017; 60: 9097-9113
- 35 Alqahtani S. Expert Opin Drug Metab Toxicol 2017; 13: 1147-1158
- 36 Sheridan RP. J Chem Inf Model 2022; 62: 3477-3485
- 37 Lu Y, Knapp M, Crawford K. et al. J Mol Biol 2017; 429: 1684-1704
- 38 Dirar AI, Waddad AY, Mohamed MA. et al. Int J Pharm Sci 2016; 8 (05) 8
- 39 Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR. Br J Pharmacol 2009; 153 S1 S7-S26
- 40 Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. J Comput Aided Mol Des 2013; 27 (03) 221-234
- 41 Du J, Sun H, Xi L. et al. J Comput Chem 2011; 32 (13) 2800-2809
- 42 Halgren TA. J Chem Inf Model 2009; 49 (02) 377-389